It means that institutional investors focused on the sector largely have passed on the pipeline. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. While anything is possible, I would not anticipate a miracle here. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. *Stock Advisor returns as of November 20, 2020. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. The stock had gained some traction after they announced the Ocugen merger in April. The median estimate. That's right -- they think these 10 stocks are even better buys. All rights reserved. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Please check your download folder. This can prove to be a costly lesson to learn. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. For now, though, what happens in India stays in India. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Type a symbol or company name. Conditions have only become worse since that time. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Objective investors could have clearly seen then that there actually were significant reasons to be concerned. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Even before that point, the most promising candidates generally can find funding. Making the world smarter, happier, and richer. Cost basis and return based on previous market day close. The Ocugen deal is a way to salvage some limited value. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Literally, zero. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. Investors need to understand the risk profile here. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. I will concede this: The one great thing about the stock market is there is a style for everyone. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. How can we possibly evaluate a stock on a fundamental basis with that being reality? Sign up below to get this incredible offer! Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Start trading Options with Saxo today. But if they do, Ocugen stock at the least looks like an intriguing bet. The second is that the balance sheet still needs some help. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Keith Speights owns shares of Pfizer. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Long-term debt of $1.6 million is not a back-breaker either. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Ocugen isnt a promotional, fly-by-night penny stock. A $30 million market capitalization doesnt mean Ocugen has no chance. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. Investors should worry about companies with no revenue even under the best of circumstances. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Do not expect a recovery in Ocugen stock. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. Plus500. That's not going to happen now. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. Sign up below to get this incredible offer! In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Even at around 40 cents per share, I would consider Ocugen stock overvalued. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. This requires no immediate effort on your part. Accordingly, the analyst rates OCGN a Neutral (i.e. Custom BMW. But there is no question some big-name stocks performed better than others along the way. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. 1125 N. Charles St, Baltimore, MD 21201. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. The Ocugen deal is a way to salvage some limited value. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. The FDA's decision not to issue EUA really wasn't all that surprising, though. quotes delayed at least 15 minutes, all others at least 20 minutes. ET on Friday. Its all about choice. At the beginning of 2020, Ocugen shares were trading at just 47 cents. The latest closing stock price for Ocugen as of March 03, 2023 is. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. But realizing value in practice usually is a difficult endeavor. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What Is the Best EV Stock to Buy Now? Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. Type a symbol or company name. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. That doesnt mean success is guaranteed. Ocugen estimates the drug could have as many as 63,000 potential patients. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. If Ocugen goes up, you can still profit. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. Unfortunately for longs, OCGN is much closer to the worst of conditions. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." In this case, shares rallied about four-fold in just a few days. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. However, sometimes the optimism isn't justified. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. As of this writing, Matt did not hold a position in any of theaforementioned securities. Hold) without suggesting a price target. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. 1125 N. Charles St, Baltimore, MD 21201. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. How long might it take for Ocugen to win full FDA approval for Covaxin? The odds of Ocugen stock winding up at zero are material. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Create your Watchlist to save your favorite quotes on Nasdaq.com. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. Click here to see what Matt has up his sleeve now. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Histogenics itself highlights the risks involved in small-cap biotech. That product drives the current bull case for Ocugen stock. That's right -- they think these 10 stocks are even better buys. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. 1125 N. Charles St, Baltimore, MD 21201. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. Pricing likely would be favorable, given the lack of alternative treatments. *Average returns of all recommendations since inception. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. These options will be cheaper than owning the stock itself. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. If you missed that action, you missed all the gains. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. That said, for investors who understand the potential downside, there is an intriguing story here. quotes delayed at least 15 minutes, all others at least 20 minutes. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. So, what goes wrong? Thats the thing with these low-priced penny stocks. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . These symbols will be available throughout the site during your session. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. From a near-term standpoint, there are two key risks. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. For priority reviews, the timeline for an approval decision is reduced to six months. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. There's still a chance that the vaccine could receive a green light in Canada. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. Typically, I care little about financials with biotechs. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The Motley Fool->. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. But any success they find will be without me as a shareholder. The Motley Fool->. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. Type a symbol or company name. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. Copyright In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Copyright 2023 InvestorPlace Media, LLC. These symbols will be available throughout the site during your session. Most biotech companies have intriguing stories on paper; Ocugen is no different. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. 2023 InvestorPlace Media, LLC. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Maybe. Ocugen had to go an unusual route to go public. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Written by Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. It has real management. Invest better with The Motley Fool. Create your Watchlist to save your favorite quotes on Nasdaq.com. Source: Chart courtesy of StockCharts.com. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. *Stock Advisor returns as of June 7, 2021. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. 1125 N. Charles St, Baltimore, MD 21201. The potential synergies of such a union do not seem clear. What Is the Best EV Stock to Buy Now? One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. The Motley Fool recommends Moderna Inc. To make the world smarter, happier, and richer. Our 3 Top Picks. Investing is always a game of balancing risk and reward. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels.